Payment overview · 2025
General Payments
$456.38
23 reported records · 15 companies
Healthcare provider profile · identity verified
David K Meredith, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GONZALES, TX · NPI 1427041383
Verified facts
What the public records show
CMS Open Payments records show David K Meredith, D.O. received $456.38 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.65 | 16.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.12 | 16.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.85 | 8.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.38 | 6.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.42 | 6.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.56 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.96 | 5.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.75 | 5.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.85 | 4.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.81 | 4.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.25 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.22 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.62 | 3.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.32 | 3.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.62 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $456.38 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.65 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.67 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $28.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 446 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 71 |
| Gabapentin | Gabapentin | 262 | 78 |
| Furosemide | Furosemide | 236 | 69 |
| Losartan Potassium | Losartan Potassium | 234 | 63 |
| Potassium Chloride | Potassium Chloride | 209 | 56 |
| Carvedilol | Carvedilol | 171 | 46 |
| Metformin Hcl | Metformin Hcl | 164 | 42 |
| Lisinopril | Lisinopril | 161 | 38 |
| Famotidine | Famotidine | 152 | 37 |
| Eliquis | Apixaban | 150 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 43 |
| Allopurinol | Allopurinol | 139 | 29 |
| Omeprazole | Omeprazole | 136 | 47 |
| Tramadol Hcl | Tramadol Hcl | 136 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 33 |
| Ozempic | Semaglutide | 125 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 30 |
| Alendronate Sodium | Alendronate Sodium | 93 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 24 |
| Jardiance | Empagliflozin | 76 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 74 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 72 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 72 | 17 |
| Valsartan | Valsartan | 70 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 15 |
| Clonazepam | Clonazepam | 69 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 21 |
| Trazodone Hcl | Trazodone Hcl | 62 | 20 |
| Trulicity | Dulaglutide | 62 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 15 |
| Alprazolam | Alprazolam | 54 | 18 |
| Prednisone | Prednisone | 54 | 33 |
| Glipizide | Glipizide | 52 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 11 |
| Cephalexin | Cephalexin | 47 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 35 |
| Metolazone | Metolazone | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | 15 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Celecoxib | Celecoxib | 30 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 18 |
| Meloxicam | Meloxicam | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Cefdinir | Cefdinir | 28 | 28 |
| Estradiol | Estradiol | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Atenolol | Atenolol | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Kelnor 1-50 | Ethynodiol D-Ethinyl Estradiol | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $456.38 · 23 records | Novo Nordisk Inc | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, FARXIGA, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PROCLAIM, PROQUAD, REXULTI, ROTATEQ, TRINTELLIX, VAXELIS, VAXNEUVANCE, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error